Lawrence K. Cohen
Chief Executive Officer at VIA PHARMACEUTICALS, INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Douglass Given | M | 71 |
VIA Pharmaceuticals, Inc. /Old/
 VIA Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology VIA Pharmaceuticals, Inc. develops pharmaceutical products. It focuses on small-molecule drugs that target inflammation in the blood vessel wall as an innovative approach to treatment of cardiovascular disease. The company's strategy is to identify, acquire and develop compounds that intervene in the process of vascular inflammation, to reduce the incidence of major cardiovascular events and provide a significant clinical benefit to patients. It was founded in June, 2004 by Thomas Quertermous, Adeoye Y. Olukotun and Douglass B. Given. VIA is headquartered in San Francisco, CA.
Health2047, Inc.
 Health2047, Inc. Investment ManagersFinance Part of American Medical Association, Health2047, Inc. is a healthcare transformation company based in Menlo Park, CA. The company focuses on systemic transformation in the areas of data, chronic disease, and productivity to make healthcare more affordable, equitable, and with better outcomes. Health2047 invests in early-stage companies and provides a world-class network of entrepreneurs and mentors. Lawrence K. Cohen has been the CEO of the company since 2017.
First Mile Care, Inc.
 First Mile Care, Inc. Medical/Nursing ServicesHealth Services First Mile Care, Inc. is a preventative chronic care company that offers a no-cost prevention program to help avoid type 2 diabetes. The company is based in Menlo Park, CA and was founded by Karl Ronn, who has been the CEO since incorporation. The company enables physicians to extend their medical practices and reduce prediabetes risks by providing affordable, scalable, and sustainable solutions. First Mile Care helps physicians, participants, and coaches work together to improve health outcomes and prevent type 2 diabetes. Physicians prescribe the proven prevention program, while Medicare covers the costs. First Mile Care provides the latest affordable, scalable, and sustainable resources for preventing chronic conditions such as prediabetes. | 11 years |
| Steven Meehan | M | 59 | 7 years | |
| Karl Ronn | M | - |
First Mile Care, Inc.
First Mile Care, Inc. Medical/Nursing ServicesHealth Services First Mile Care, Inc. is a preventative chronic care company that offers a no-cost prevention program to help avoid type 2 diabetes. The company is based in Menlo Park, CA and was founded by Karl Ronn, who has been the CEO since incorporation. The company enables physicians to extend their medical practices and reduce prediabetes risks by providing affordable, scalable, and sustainable solutions. First Mile Care helps physicians, participants, and coaches work together to improve health outcomes and prevent type 2 diabetes. Physicians prescribe the proven prevention program, while Medicare covers the costs. First Mile Care provides the latest affordable, scalable, and sustainable resources for preventing chronic conditions such as prediabetes. | - |
| H. Bingham | M | 79 |
Health2047, Inc.
Health2047, Inc. Investment ManagersFinance Part of American Medical Association, Health2047, Inc. is a healthcare transformation company based in Menlo Park, CA. The company focuses on systemic transformation in the areas of data, chronic disease, and productivity to make healthcare more affordable, equitable, and with better outcomes. Health2047 invests in early-stage companies and provides a world-class network of entrepreneurs and mentors. Lawrence K. Cohen has been the CEO of the company since 2017. | - |
| Justin P. Klein | M | 75 |
Health2047, Inc.
Health2047, Inc. Investment ManagersFinance Part of American Medical Association, Health2047, Inc. is a healthcare transformation company based in Menlo Park, CA. The company focuses on systemic transformation in the areas of data, chronic disease, and productivity to make healthcare more affordable, equitable, and with better outcomes. Health2047 invests in early-stage companies and provides a world-class network of entrepreneurs and mentors. Lawrence K. Cohen has been the CEO of the company since 2017. | 6 years |
| Juliana Ronn | F | - |
First Mile Care, Inc.
First Mile Care, Inc. Medical/Nursing ServicesHealth Services First Mile Care, Inc. is a preventative chronic care company that offers a no-cost prevention program to help avoid type 2 diabetes. The company is based in Menlo Park, CA and was founded by Karl Ronn, who has been the CEO since incorporation. The company enables physicians to extend their medical practices and reduce prediabetes risks by providing affordable, scalable, and sustainable solutions. First Mile Care helps physicians, participants, and coaches work together to improve health outcomes and prevent type 2 diabetes. Physicians prescribe the proven prevention program, while Medicare covers the costs. First Mile Care provides the latest affordable, scalable, and sustainable resources for preventing chronic conditions such as prediabetes. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| James Gordon Stewart | M | 71 |
VIA Pharmaceuticals, Inc. /Old/
VIA Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology VIA Pharmaceuticals, Inc. develops pharmaceutical products. It focuses on small-molecule drugs that target inflammation in the blood vessel wall as an innovative approach to treatment of cardiovascular disease. The company's strategy is to identify, acquire and develop compounds that intervene in the process of vascular inflammation, to reduce the incidence of major cardiovascular events and provide a significant clinical benefit to patients. It was founded in June, 2004 by Thomas Quertermous, Adeoye Y. Olukotun and Douglass B. Given. VIA is headquartered in San Francisco, CA. | 4 years |
| Karen S. Wright | F | 69 |
VIA Pharmaceuticals, Inc. /Old/
VIA Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology VIA Pharmaceuticals, Inc. develops pharmaceutical products. It focuses on small-molecule drugs that target inflammation in the blood vessel wall as an innovative approach to treatment of cardiovascular disease. The company's strategy is to identify, acquire and develop compounds that intervene in the process of vascular inflammation, to reduce the incidence of major cardiovascular events and provide a significant clinical benefit to patients. It was founded in June, 2004 by Thomas Quertermous, Adeoye Y. Olukotun and Douglass B. Given. VIA is headquartered in San Francisco, CA. | 6 years |
| Anastasios Konidaris | M | 57 | - | |
| Sheng Da Zan | M | 61 | 3 years | |
| David Warren Carter | M | 84 |
Somatix Therapy Corp.
 Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | 6 years |
| John Randolph Larson | M | 77 | - | |
| Brendan P. Rae | M | - |
VIA Pharmaceuticals, Inc. /Old/
VIA Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology VIA Pharmaceuticals, Inc. develops pharmaceutical products. It focuses on small-molecule drugs that target inflammation in the blood vessel wall as an innovative approach to treatment of cardiovascular disease. The company's strategy is to identify, acquire and develop compounds that intervene in the process of vascular inflammation, to reduce the incidence of major cardiovascular events and provide a significant clinical benefit to patients. It was founded in June, 2004 by Thomas Quertermous, Adeoye Y. Olukotun and Douglass B. Given. VIA is headquartered in San Francisco, CA. | 5 years |
| James Stewart | M | - | 4 years | |
| Thomas Quertermous | M | 71 |
VIA Pharmaceuticals, Inc. /Old/
VIA Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology VIA Pharmaceuticals, Inc. develops pharmaceutical products. It focuses on small-molecule drugs that target inflammation in the blood vessel wall as an innovative approach to treatment of cardiovascular disease. The company's strategy is to identify, acquire and develop compounds that intervene in the process of vascular inflammation, to reduce the incidence of major cardiovascular events and provide a significant clinical benefit to patients. It was founded in June, 2004 by Thomas Quertermous, Adeoye Y. Olukotun and Douglass B. Given. VIA is headquartered in San Francisco, CA. | 3 years |
| Andrew Cohen | M | 52 | 6 years | |
| Bart M. Schwartz | M | 77 | 3 years | |
| Mark Bagnall | M | 67 | 4 years | |
| Michael Perry | M | 64 |
VIA Pharmaceuticals, Inc. /Old/
VIA Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology VIA Pharmaceuticals, Inc. develops pharmaceutical products. It focuses on small-molecule drugs that target inflammation in the blood vessel wall as an innovative approach to treatment of cardiovascular disease. The company's strategy is to identify, acquire and develop compounds that intervene in the process of vascular inflammation, to reduce the incidence of major cardiovascular events and provide a significant clinical benefit to patients. It was founded in June, 2004 by Thomas Quertermous, Adeoye Y. Olukotun and Douglass B. Given. VIA is headquartered in San Francisco, CA. | 5 years |
| David T. Howard | M | 74 | - | |
| Adeoye Olukotun | M | 79 | 4 years | |
| Tilmann M. Brotz | M | - | - | |
| Fred Craves | M | 78 | 7 years | |
| Raymond Tabibiazar | M | 53 | 2 years | |
| Zhen Ping Zhu | M | 59 | - | |
| Edward Chiang | M | - | 5 years | |
| Eva Heyman | F | - | - | |
| Olivier Danos | M | 66 |
Somatix Therapy Corp.
Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | 2 years |
| Kyle Carver | M | - | 8 years | |
| Jun S. Yoon | M | - | 6 years | |
| Winnie H. Wan | M | - |
Somatix Therapy Corp.
Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | 3 years |
| Rebecca Taub | M | 71 | 3 years | |
| Steven Jungles | M | 58 |
Somatix Therapy Corp.
Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | 4 years |
| Ann Lenich Hards | M | - |
Somatix Therapy Corp.
Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | 1 years |
| Richard L. Anderson | M | 84 | 2 years | |
| Robert W. Kuhn | M | - |
Somatix Therapy Corp.
Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | 3 years |
| James C. Gilstrap | M | 88 | - | |
| Adriaan Ligtenberg | M | 68 |
Health2047, Inc.
Health2047, Inc. Investment ManagersFinance Part of American Medical Association, Health2047, Inc. is a healthcare transformation company based in Menlo Park, CA. The company focuses on systemic transformation in the areas of data, chronic disease, and productivity to make healthcare more affordable, equitable, and with better outcomes. Health2047 invests in early-stage companies and provides a world-class network of entrepreneurs and mentors. Lawrence K. Cohen has been the CEO of the company since 2017. | 6 years |
| Peter Bluford | M | - |
Somatix Therapy Corp.
Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | 4 years |
| Edward O. Lanphier | M | 67 |
Somatix Therapy Corp.
Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | 5 years |
| John Monahan | M | 77 |
Somatix Therapy Corp.
Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | 3 years |
| Inder Mohan Verma | M | 76 |
Somatix Therapy Corp.
Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | - |
| John T. Potts | M | 92 |
Somatix Therapy Corp.
Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | - |
| Larry Witte | M | 79 | 6 years | |
| Jun Yoon | M | 46 | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 45 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Lawrence K. Cohen
- Personal Network
